Protagen is able to detect autoantibodies for the prediction and monitoring of immune-related adverse events (irAEs), as well as therapeutic response for patients undergoing cancer immunotherapy, helping pharmaceutical and biotech companies develop safer, more effective immunotherapies.
Immune system profiling and the prediction of immune-related Adverse Events (irAEs)
Despite the enormous potential of cancer immunotherapy, many patients receiving such treatments experience debilitating and sometimes-fatal irAEs. Characterized by an over-activation of the immune system, irAEs pose a significant barrier to immunotherapy success, as they have led to the FDA halting clinical trials—slowing the development of effective cancer immunotherapies.
The detailed analysis of patient immune systems holds the key to understanding the biology of irAEs and predicting therapeutic response. The figure below displays data from a malignant melanoma study that applied the Cancer Immunotherapy Array.
This study identified several autoantibodies significant in both the prediction of colitis and irAEs in general in pre-treatment samples of checkpoint inhibitor-treated patients (treated either with a PD-1 inhibitor, a CTLA4 inhibitor or a combination of both, in the monotherapy setting the biomarker profile was distinctly different). Two examples are given below.
For more information on how autoantibodies can bolster cancer immunotherapy development, download the eBook.
Predicting progression-free and overall survival
Immunotherapies such as therapeutic vaccination and checkpoint inhibition hold great promise for treating and potentially even curing cancer, but currently work effectively for only a limited number of patients. Being able to predict treatment response will allow clinicians to make more informed and safer decisions for patients, and will avoid the treatment of patients who do not stand to benefit from the therapy in the first place.
In addition to acting as measurable indicators of the onset of irAEs in patients undergoing immunotherapy, the potential of autoantibodies to predict progression-free survival (PFS) and overall survival in cancer patients has also been demonstrated by Protagen. In the figure below, autoantibodies raised against cytokines and cytokine receptors were found both in autoimmune disease and cancer patients, where autoantibodies were associated with a higher progression-free survival in checkpoint inhibitor-treated patients.
To find out more about how autoantibodies can be used to predict therapeutic outcomes, read the immuno-oncology eBook.
Protagen is dedicated to the development of precision medicine tools that are giving pharmaceutical and biotech companies the power to develop safer anti-cancer drugs, and enabling clinicians to select the right therapy for the right patient.
Protagen is expanding its NavigAID offering to support the development of immunotherapeutic anticancer drugs, owing to the role played by autoantibodies in cancer as well as autoimmune disease.
SeroTag® is Protagen’s proprietary biomarker discovery engine, which is used to discover and validate novel biomarkers that can help stratify different cancer indications and autoimmune diseases.
Get in touch
Improving the treatment of cancer and autoimmune disease is our passion, and we always welcome the chance to discuss these topics with current and prospective customers, patients and clinicians alike.